{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,29]],"date-time":"2025-08-29T10:43:55Z","timestamp":1756464235548,"version":"3.41.2"},"reference-count":20,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T00:00:00Z","timestamp":1644364800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100003725","name":"National Research Foundation of Korea","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003725","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pediatr."],"abstract":"<jats:sec><jats:title>Introduction<\/jats:title><jats:p>Tuberculosis (TB) spondylitis, also known as Pott's disease, is a severe form of extrapulmonary TB. Infliximab treatment for Crohn's disease (CD) patients increases the risk of TB, and is likely to increase the risk of TB spondylitis as well.<\/jats:p><\/jats:sec><jats:sec><jats:title>Case Presentation<\/jats:title><jats:p>We report a rare case of TB spondylitis development in a 16-year-old female with CD. She had a close household contact of active pulmonary TB and received contact investigation. She was diagnosed with latent TB 1 month before the diagnosis of CD, and had started a latent TB treatment regimen with isoniazid for 9 months. At 5 months from the start of latent TB treatment, infliximab was started. Approximately 1 year after infliximab treatment, her infusion interval was shortened from every 8 weeks to every 4 weeks owing to secondary loss of response due to nonimmunogenic pharmacokinetic failure. One month later, miliary TB developed and infliximab was stopped. She received a miliary TB treatment regimen for 6 months, curing the disease. Three months later, spinal TB was incidentally detected on abdominal computed tomography. She received a TB treatment regimen for 12 months, curing spinal TB. Currently, she is receiving vedolizumab to treat CD and is in clinical remission. Although this patient has sufficiently been treated at each stage of TB development, particularly for latent TB and miliary TB, TB spondylitis still developed.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>Considering that TB spondylitis developed despite sufficient treatment at each stage, pediatric gastroenterologists should stay cautious when using anti-tumor necrosis factor agents in patients with inflammatory bowel disease with a history of latent TB.<\/jats:p><\/jats:sec>","DOI":"10.3389\/fped.2021.802298","type":"journal-article","created":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T07:21:23Z","timestamp":1644391283000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":4,"title":["Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review"],"prefix":"10.3389","volume":"9","author":[{"given":"Jae Hoon","family":"Jung","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Sujin","family":"Choi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Youra","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dae-Chul","family":"Cho","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"So Mi","family":"Lee","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tae In","family":"Park","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Byung-Ho","family":"Choe","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Dongsub","family":"Kim","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ben","family":"Kang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2022,2,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"1053","DOI":"10.1001\/jamapediatrics.2015.1982","article-title":"Inflammatory bowel disease in children and adolescents","volume":"169","author":"Rosen","year":"2015","journal-title":"JAMA Pediatr."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1279","DOI":"10.1093\/ecco-jcc\/jjw086","article-title":"Mucosal Healing in Paediatric Patients with Moderate-to-Severe Luminal Crohn's Disease Under Combined Immunosuppression: Escalation versus Early Treatment","volume":"10","author":"Kang","year":"2016","journal-title":"J Crohns Colitis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1","DOI":"10.5223\/pghn.2018.21.1.1","article-title":"Early biologic treatment in pediatric crohn's disease: catching the therapeutic window of opportunity in early disease by treat-to-target","volume":"21","author":"Kang","year":"2018","journal-title":"Pediatr Gastroenterol Hepatol Nutr."},{"key":"B4","doi-asserted-by":"publisher","first-page":"8","DOI":"10.1007\/PL00011973","article-title":"Spinal tuberculosis (Pott's disease): its clinical presentation, surgical management, and outcome. A survey study on 694 patients","volume":"24","author":"Turgut","year":"2001","journal-title":"Neurosurg Rev."},{"key":"B5","doi-asserted-by":"publisher","first-page":"216","DOI":"10.4184\/asj.2014.8.2.216","article-title":"Comparison of pyogenic spondylitis and tuberculous spondylitis","volume":"8","author":"Lee","year":"2014","journal-title":"Asian Spine J."},{"key":"B6","doi-asserted-by":"publisher","first-page":"S199","DOI":"10.1086\/429998","article-title":"Tumor necrosis factor and its blockade in granulomatous infections: differential modes of action of infliximab and etanercept?","volume":"3","author":"Ehlers","year":"2005","journal-title":"Clin Infect Dis."},{"key":"B7","doi-asserted-by":"publisher","first-page":"800","DOI":"10.1136\/thx.2005.046797","article-title":"BTS recommendations for assessing risk and for managing Mycobacterium tuberculosis infection and disease in patients due to start anti-TNF-alpha treatment","volume":"60","year":"2005","journal-title":"Thorax"},{"key":"B8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.arbr.2015.11.005","article-title":"Consensus document on prevention and treatment of tuberculosis in patients for biological treatment","volume":"52","author":"Mir Viladrich","year":"2016","journal-title":"Arch Bronconeumol."},{"key":"B9","doi-asserted-by":"publisher","first-page":"4","DOI":"10.5217\/ir.2018.16.1.4","article-title":"Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 1: risk assessment","volume":"16","author":"Park","year":"2018","journal-title":"Intest Res."},{"key":"B10","doi-asserted-by":"publisher","first-page":"17","DOI":"10.5217\/ir.2018.16.1.17","article-title":"Asian Organization for Crohn's and Colitis and Asia Pacific Association of Gastroenterology consensus on tuberculosis infection in patients with inflammatory bowel disease receiving anti-tumor necrosis factor treatment. Part 2: management","volume":"16","author":"Park","year":"2018","journal-title":"Intest Res."},{"key":"B11","doi-asserted-by":"publisher","first-page":"1766","DOI":"10.1002\/art.21043","article-title":"Effectiveness of recommendations to prevent reactivation of latent tuberculosis infection in patients treated with tumor necrosis factor antagonists","volume":"52","author":"Carmona","year":"2005","journal-title":"Arthritis Rheum."},{"key":"B12","doi-asserted-by":"publisher","first-page":"756","DOI":"10.1002\/art.22768","article-title":"Biobadaser Group. Risk of tuberculosis in patients treated with tumor necrosis factor antagonists due to incomplete prevention of reactivation of latent infection","volume":"57","author":"G\u00f3mez-Reino","year":"2007","journal-title":"Arthritis Rheum."},{"key":"B13","doi-asserted-by":"publisher","first-page":"150","DOI":"10.4103\/0019-5413.93676","article-title":"Spinal tuberculosis in children: Retrospective analysis of 124 patients","volume":"46","author":"Moon","year":"2012","journal-title":"Indian J Orthop."},{"key":"B14","doi-asserted-by":"publisher","first-page":"1890","DOI":"10.1097\/00007632-199310000-00028","article-title":"Evaluation of the risk of instrumentation as a foreign body in spinal tuberculosis. Clinical and biologic study","volume":"18","author":"Oga","year":"1993","journal-title":"Spine (Phila Pa 1976)"},{"key":"B15","doi-asserted-by":"publisher","first-page":"366","DOI":"10.1016\/j.eimce.2018.04.009","article-title":"Tuberculosis in immunosuppressed patients","volume":"36","author":"Machuca","year":"2018","journal-title":"Enferm Infecc Microbiol Clin (Engl Ed)."},{"key":"B16","doi-asserted-by":"publisher","first-page":"699","DOI":"10.1056\/NEJMoa1215734","article-title":"Vedolizumab as induction and maintenance therapy for ulcerative colitis","volume":"369","author":"Feagan","year":"2013","journal-title":"N Engl J Med."},{"key":"B17","doi-asserted-by":"publisher","first-page":"711","DOI":"10.1056\/NEJMoa1215739","article-title":"Vedolizumab as induction and maintenance therapy for Crohn's disease","volume":"369","author":"Sandborn","year":"2013","journal-title":"N Engl J Med."},{"key":"B18","doi-asserted-by":"publisher","first-page":"997","DOI":"10.1053\/j.gastro.2019.05.067","article-title":"Vedolizumab induces endoscopic and histologic remission in patients with Crohn's disease","volume":"157","author":"L\u00f6wenberg","year":"2019","journal-title":"Gastroenterology."},{"key":"B19","doi-asserted-by":"publisher","first-page":"839","DOI":"10.1136\/gutjnl-2015-311079","article-title":"The safety of vedolizumab for ulcerative colitis and Crohn's disease","volume":"66","author":"Colombel","year":"2017","journal-title":"Gut."},{"key":"B20","doi-asserted-by":"publisher","first-page":"e486","DOI":"10.1016\/j.crohns.2013.03.004","article-title":"Tuberculosis in anti-TNF-\u03b1 treated patients remains a problem in countries with an intermediate incidence: analysis of 25 patients matched with a control population","volume":"7","author":"Abreu","year":"2013","journal-title":"J Crohns Colitis."}],"container-title":["Frontiers in Pediatrics"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.802298\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,2,9]],"date-time":"2022-02-09T07:21:24Z","timestamp":1644391284000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fped.2021.802298\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,2,9]]},"references-count":20,"alternative-id":["10.3389\/fped.2021.802298"],"URL":"https:\/\/doi.org\/10.3389\/fped.2021.802298","relation":{},"ISSN":["2296-2360"],"issn-type":[{"type":"electronic","value":"2296-2360"}],"subject":[],"published":{"date-parts":[[2022,2,9]]},"article-number":"802298"}}